Physician profile
Tiffany Pickrell
NPI 1154087773
$1,768.15
in general payments reported to CMS, 2019-2025
29 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $425 · 2023: $541 · 2024: $492 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324 · Education: $18.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.17 |
| Education | $18.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $252.66 | 2022 | |
| Jazz Pharmaceuticals INC. | $178.51 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $168.79 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $148.90 | 2023-2025 | |
| Janssen Biotech, INC. | $114.82 | 2022-2025 | Erleada, Rybrevant, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $109.06 | 2022-2025 | Opdivo, Opdualag |
| Array Biopharma INC | $87.51 | 2022-2025 | Mektovi, Lorbrena, Braftovi |
| Pfizer INC. | $74.06 | 2022-2025 | |
| Incyte Corporation | $70.94 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $63.71 | 2023-2025 | Keytruda, Welireg |
| Taiho Oncology, INC. | $55.98 | 2024-2025 | |
| Seagen INC. | $55.37 | 2023 | Tukysa |
| Abbvie INC. | $49.91 | 2023-2024 | |
| Gilead Sciences, INC. | $37.98 | 2024-2025 | Trodelvy |
| Celgene Corporation | $36.26 | 2022-2023 | Reblozyl |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $33.30 | 2023 | Tazverik |
| Stemline Therapeutics INC. | $30.53 | 2023-2025 | Orserdu |
| Blueprint Medicines Corporation | $22.41 | 2025 | Ayvakit |
| Tempus Ai, INC | $21.82 | 2024 | |
| Glaxosmithkline, LLC. | $19.85 | 2023 | Ojjaara, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $17.15 | 2024 | |
| Kyowa Kirin, INC. | $16.20 | 2023 | Poteligeo |
| Pharmacyclics LLC, An Abbvie Company | $15.87 | 2022 | |
| Apellis Pharmaceuticals, INC. | $15.72 | 2023 | Empaveli |
| Astellas Pharma US INC | $14.92 | 2022 | |
| Daiichi Sankyo INC. | $14.86 | 2024 | Enhertu |
| Tolmar Pharmaceuticals, INC. | $13.76 | 2022 | |
| Puma Biotechnology, INC. | $13.75 | 2024 | |
| Genentech USA, INC. | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Pickrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.